
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic is a well-established medical device company with a diverse product portfolio and strong performance in key markets, including the United States, Western Europe, and Japan. Its successful Symplicity Spyral Renal Denervation System and undervalued stock position suggest potential for significant future growth, though potential risks and challenges from competition and market conditions should be closely monitored.
Bears say
Medtronic is currently facing several key risks that could impact its future growth and profitability, including potential market share losses to competitor product launches, disappointing sales from new products, lower-than-expected margins, and negative currency impacts. Additionally, the company's global presence makes it susceptible to macroeconomic volatility, and its capital allocation strategy may face challenges if management is unable to make effective investments. Furthermore, the separation of its Diabetes business could create uncertainties and risks, and potential underperformance in upcoming clinical trials for key devices may also impact future earnings. Despite the company's strong portfolio and expected revenue growth, these risks contribute to our negative outlook on Medtronic's stock.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares